You are here
INVOKANA®: An SGLT2 inhibitor that removes glucose from the body1
Mechanism of action
- The capacity for reabsorption of glucose is increased in patients with type 2 diabetes, contributing to hyperglycemia2
- Reducing glucose reabsorption, increasing urinary glucose excretion
- INVOKANA® results in the excretion of approximately 100 grams of glucose per day1
References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-142.